LONA · LeonaBio, Inc.
$7.92
-0.02 (-0.25%)
At close · Aug 31
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based upon the Company's current operating plan, it estimates that its $51.1 million of cash, cash equivalents and investments at June 30, 2026 may not be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months which raises substantial doubt as to our ability to continue as a going concern following the date of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 14, 2026
Market Cap
$74.81M
Shares
9.42M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Mark Litton | Ph.D., President and Chief Executive Officer | $1,423,814 |
| Javier San Martin | M.D., Chief Medical Officer | $810,134 |
| Mark Worthington | General Counsel, Chief Compliance Officer and Corporate Secretary | $731,477 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mark Litton | Ph.D., President and Chief Executive Officer | $3,175,009 |
| Rachel Lenington | Former Chief Operating Officer and Chief Development Officer | $1,600,070 |
| Andrew Gengos | Former Chief Financial Officer and Chief Business Officer | $1,459,708 |
| Mark Worthington | General Counsel, Chief Compliance Officer and Corporate Secretary | $1,337,509 |
| Kevin Church | Ph.D., Chief Scientific Officer | $1,336,071 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark Litton | Ph.D., President and Chief Executive Officer | $2,276,537 |
| Andrew Gengos | Former Chief Financial Officer and Chief Business Officer | $1,325,881 |
| Hans Moebius | M.D., Ph.D Former Chief Medical Officer | $1,292,474 |
| Rachel Lenington | Former Chief Operating Officer and Chief Development Officer | $1,231,199 |
| Mark Worthington | General Counsel, Chief Compliance Officer and Corporate Secretary | $1,014,684 |
| Kevin Church | Ph.D., Chief Scientific Officer | $991,884 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Mark Litton | Ph.D., President and Chief Executive Officer | $3,775,199 |
| Hans Moebius | M.D., Ph.D Former Chief Medical Officer | $2,103,733 |
| Rachel Lenington | Chief Operating Officer | $2,028,896 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mark Litton | Ph.D., President and Chief Executive Officer | $2,954,689 |
| Rachel Lenington | Chief Operating Officer | $2,555,578 |
| Hans Moebius | M.D., Ph.D Chief Medical Officer | $2,228,321 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Leen Kawas | Ph.D., President and Chief Executive Officer | $1,349,042 |
| Hans Moebius | M.D., Ph.D., Chief Medical Officer | $1,018,488 |
| Glenna Mileson | Chief Financial Officer | $709,020 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Leen Kawas | Ph.D., President and Chief Executive Officer | $287,015 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Rachel Lenington | chief operating officer and chief development officer | Terminated | 2024-10-07 |
| Andrew Gengos | chief business officer and chief financial officer | Terminated | 2024-10-07 |
| Robert Renninger | principal financial officer | Appointed | 2024-09-17 |
| Robert Renninger | principal accounting officer | Appointed | 2024-09-17 |
| Rachel Lenington | chief development officer | Terminated | 2024-09-17 |
| Rachel Lenington | chief operating officer and chief development officer | Terminated | 2024-09-17 |
| Andrew Gengos | chief business officer | Terminated | 2024-09-17 |
| Andrew Gengos | chief business officer and chief financial officer | Terminated | 2024-09-17 |
| Dr. Hans Moebius | Chief Medical Officer | Resigned | 2024-01-08 |
| Glenna Mileson | Chief Financial Officer | Retired | 2023-05-22 |
| Andrew Gengos | Chief Financial Officer and Chief Business Officer | Appointed | 2023-05-22 |
| Glenna Mileson | Chief Financial Officer | Resigned | 2023-05-22 |
| Andrew Gengos | Chief Financial Officer and Chief Business Officer | Appointed | 2023-05-22 |
| Glenna Mileson | Chief Financial Officer | Resigned | 2023-05-22 |
| Michael Panzara | director | Appointed | 2022-03-21 |
| Grant Pickering | Board of Directors | Appointed | 2022-01-31 |
| Grant Pickering | director | Appointed | 2022-01-31 |
| Leen Kawas | President and Chief Executive Officer | Resigned | 2021-10-21 |
| Rachel Lenington | Chief Operating Officer | Appointed | 2021-10-21 |
| Leen Kawas | member of the Company's Board of Directors | Resigned | 2021-10-21 |
| Mark Litton | member of the Company's Board of Directors | Appointed | 2021-10-21 |
| Mark Litton | Chief Executive Officer | Appointed | 2021-10-21 |
| Rachel Lenington | chief operating officer | Appointed | 2021-10-21 |
| Mark Litton | member of Athira's board of directors | Appointed | 2021-10-21 |
| Mark Litton | president and chief executive officer | Appointed | 2021-10-21 |
Key facts
CIK
1620463
CUSIP
04746L203
13F (30d)
44 filings
43 filers
Visit website
Investor relations